Presymptomatic genetic testing for neurodegenerative diseases can help patients make effective treatment decisions, but the medical profession needs to ensure that the increasing use of the tests is done responsibly.
Medical ethicists have discussed the use of race classification in determining disease prevalence and the response of specific ethnic groups to different medications.
The AMA's Code of Medical Ethics' opinion on the use of databanks in genomic research requires informed consent by groups and individuals who are subjects of research.